| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/03/2011 | US20110053983 (5r)-1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives having cb1-antagonistic activity |
| 03/03/2011 | US20110053982 Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors |
| 03/03/2011 | US20110053976 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 03/03/2011 | US20110053974 Carboxylic acid compound |
| 03/03/2011 | US20110053973 Compounds as tyrosine kinase modulators |
| 03/03/2011 | US20110053962 Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition |
| 03/03/2011 | US20110053961 Substituted xanthine derivatives |
| 03/03/2011 | US20110053960 Method for treating pain syndrome and other disorders |
| 03/03/2011 | US20110053959 Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 03/03/2011 | US20110053958 Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto |
| 03/03/2011 | US20110053952 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors |
| 03/03/2011 | US20110053950 4-benzylidene-3-methylpiperidine aryl carboxamide compounds useful as faah inhibitors |
| 03/03/2011 | US20110053949 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors |
| 03/03/2011 | US20110053943 CARBAMATE AND UREA INHIBITORS OF 11ß-HYDROXYSTEROID DEHYDROGENASE 1 |
| 03/03/2011 | US20110053940 3,4-substituted piperidine derivatives as renin inhibitors |
| 03/03/2011 | US20110053936 substituted spiro[cycloalkyl-1,3'-indol]-2'(1'h)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| 03/03/2011 | US20110053935 Fused pyridines active as inhibitors of c-met |
| 03/03/2011 | US20110053931 Quinoline compounds and methods of use |
| 03/03/2011 | US20110053930 Inhibitors of the bmp signaling pathway |
| 03/03/2011 | US20110053925 Hydroxamate-Based Inhibitors of Deacetylases |
| 03/03/2011 | US20110053924 Substituted piperidines as renin inhibitors |
| 03/03/2011 | US20110053920 Substituted bicyclic pyrimidines |
| 03/03/2011 | US20110053918 Gamma secretase modulators |
| 03/03/2011 | US20110053917 Allosteric Modulators of the A1 Adenosine Receptor |
| 03/03/2011 | US20110053911 Tricyclic derivatives as inhibitors of poly(adp-ribose) polymerase (parp) |
| 03/03/2011 | US20110053908 Azetidine-derived compounds, preparation method therefor and therapeutic use of same |
| 03/03/2011 | US20110053905 Compounds as tyrosine kinase modulators |
| 03/03/2011 | US20110053902 Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders |
| 03/03/2011 | US20110053895 Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases |
| 03/03/2011 | US20110053874 Use of flavonoide compounds for the prophylaxis and therapy of ischaemic or inflammatory heart and cardiovascular diseases |
| 03/03/2011 | US20110053873 Hsp90 inhibitors |
| 03/03/2011 | US20110053871 Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation |
| 03/03/2011 | US20110053869 Methods and compositions for inhibiting progression to chronic cardiac failure |
| 03/03/2011 | US20110053853 Use of copolymer 1 for treatment of muscular dystrophy |
| 03/03/2011 | US20110053852 Use of podocan protein in treating cardiovascular diseases |
| 03/03/2011 | US20110053847 Methods of treating vasodilatory shock |
| 03/03/2011 | US20110053841 N-terminal fgf variants having increased receptor selectivity and uses thereof |
| 03/03/2011 | US20110053217 Polynucleotides encoding signal peptide-containing molecules |
| 03/03/2011 | US20110052737 Topical skin formulations comprising botanical extracts |
| 03/03/2011 | US20110052736 Methods and materials for reducing or eliminating risk factors associated with syndrome x |
| 03/03/2011 | US20110052729 Pharmaceutical or nutraceutical composition |
| 03/03/2011 | US20110052718 Synergistic Phytoceutical Compositions |
| 03/03/2011 | US20110052683 Pharmaceutical preparation for treating cardiovascular disease |
| 03/03/2011 | US20110052682 Methods for enhancing the release and absorption of water insoluble active agents |
| 03/03/2011 | US20110052677 Modulation of srpx2-mediated angiogenesis |
| 03/03/2011 | US20110052674 Angiotensin ii receptor blocker derivatives |
| 03/03/2011 | US20110052669 Methods for modulating de novo hepatic lipogenesis by modulating xbp-1 activity |
| 03/03/2011 | US20110052650 Porous crystalline hybrid solid for adsorbing and releasing gas of biological interest |
| 03/03/2011 | US20110052643 Compounds for inflammation and immune-related uses |
| 03/03/2011 | US20110052621 Pcsk9 vaccine |
| 03/03/2011 | US20110052616 Biological materials and uses thereof |
| 03/03/2011 | US20110052594 Agents that dissolve arterial thrombi |
| 03/03/2011 | US20110052562 Benzimidazoles and analogs as rho kinase inhibitors |
| 03/03/2011 | US20110052551 Cardiac myocyte morphogenic compositions and methods of use therefor |
| 03/03/2011 | US20110052546 Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation |
| 03/03/2011 | CA2809803A1 Stabilized melanocortin ligands |
| 03/03/2011 | CA2790390A1 Novel tetrahydroisoquinoline compounds |
| 03/03/2011 | CA2772610A1 Sdf-1 delivery for treating ischemic tissue |
| 03/03/2011 | CA2772499A1 Polymorphic forms of manidipine |
| 03/03/2011 | CA2772489A1 Isotopically labeled neurochemical agents and uses thereof for diagnosing conditions and disorders |
| 03/03/2011 | CA2772164A1 Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof |
| 03/02/2011 | EP2289970A1 Biocompatible polymers, their process of manufacture and compositions containing them |
| 03/02/2011 | EP2289935A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289934A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289933A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289932A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289931A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289930A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289929A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289928A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289927A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289926A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289925A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289924A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289923A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289922A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289921A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289920A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289919A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289918A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289917A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289916A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289915A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289914A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289913A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289912A1 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 03/02/2011 | EP2289894A2 Pyrrolo-triazine compounds useful as kinase inhibitors |
| 03/02/2011 | EP2289893A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| 03/02/2011 | EP2289551A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 03/02/2011 | EP2289538A1 Use of liver growth factor (lgf) as a neural tissue regenerator |
| 03/02/2011 | EP2289531A2 Medicaments for increasing endogenous erythropoietine (EPO) |
| 03/02/2011 | EP2289521A2 Compositions and methods for use in tergeting vascular destruction |
| 03/02/2011 | EP2289507A1 Pharmaceutical compositions of CETP inhibitors |
| 03/02/2011 | EP2289504A2 SIRT1 modulators for manipulating cell/organism lifespan/stress response |
| 03/02/2011 | EP2289500A1 Retinol binding protein and transthyretin modulators for treating hypertosis, Alzheimer's disease or idiopathic intracranial hypertension |
| 03/02/2011 | EP2288384A2 Treatment of thromboangiitis obliterans by removal of autoantibodies |
| 03/02/2011 | EP2288377A1 Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction |
| 03/02/2011 | EP2288373A2 Treating dyspnea associated with acute heart failure with relaxin |
| 03/02/2011 | EP2288366A2 Method of treating chronic heart failure |
| 03/02/2011 | EP2086969B1 3-cyano-5-thiazaheteroaryl-dihydropyridine and the use thereof for the treatment of cardiovascular diseases |